Vertex Pharmaceuticals announced positive interim results at week 36 from the phase III clinical trial (code-named Rainier) of its investigational drug Povetacicept for adult IgA nephropathy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNB falls below $700
Continue fueling AI expenses! Oracle (ORCL.US) reportedly close to selling $10 billions in stocks at an 11% discount, priced at $116.
It is reported that Oracle is about to sell shares worth 10 billions USD at an 11% discount.
Synthetix Protocol DAO transfers 428,000 stolen SNX
Is cutting AI spending more beneficial? Bank of America gives a counterintuitive judgment: although “unpopular,” it may extend the economic cycle, and chip stocks could enjoy a longer profit runway.
Bank of America: Chip companies cutting capital expenditures may be “unpopular,” but it could extend the earnings cycle.
Crypto prices
More
